Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronies disease
When tirzepatide activates GLP-1 and GIP receptors, it influences systemic inflammation and immune responseprocesses that can occasionally trigger histamine release or localized inflammatory reactions in susceptible individuals
Currie, E., Schulze, A., Zechner, R., Walther, T
Ronis MJ, Badger TM, Shema SJ, et al
Risk Factors and Vulnerable Populations Certain patients face higher risks of developing foot complications during GLP-1 treatment: Diabetic Patients: Those with type 2 diabetes already have an increased risk of diabetic foot complications, including neuropathy and foot ulcers